CD40 and diffuse large B-cell lymphoma: Indeed, monoclonal antibodies targeting CD40 such as Dacetuzumab have been investigated in phase 1 and 2 clinical trials for conditions such as multiple myeloma and diffuse large B cell lymphoma (DLBCL), perhaps paving the way for a new therapeutic for other hematological malignancies such as CLL (116).